Main Article Content
Background: PD-L1 is the main ligand is expressed on many tumors including lung cancer and is expressed in hematopoietic cells and various leukemia. The aim of this study was to evaluate the expression of PD-1 gene and the evaluation of cancerous grades of NSCLC and its subclasses from lung cancer patients in Tehran hospitals using Real-Time PCR.
Materials and Methods: A total of 35 clinical samples were collected from patients with NSCLC-derived lung cancer from three hospitals in Tehran (Khatam Hospital, Athiyah Hospital, and Masih Hospital). Of the 35 samples collected in 2017, 20% of the patients were women and 80% of them were male. The range of patients’ age spectrum was 37 - 80 years. The disease grade of the patients in this study was varied and 22 different grades among them. To investigate the PDCD-1 gene expression level, after extraction of RNA and cDNA synthesis the Real-Time PCR was done and the expression of the gene was investigated.
Results: The highest grade was IIIa which contained 6 patients (17.1%). 74% of adenocarcinoma cases were in T-categories of lung cancer and 25% of patients were in grade IIIa. Patients with the grade of T3 were observed in 4 samples, 2 had adenocarcinoma and 2 with SCC with age range of 55 -62 years. The results showed that the expression of PDCD-1 increased 2.46 Fold more in patients with lung cancer than NSCLC.
Conclusion: The results of this study showed that there is a significant relationship between the PDCD1 or PD-1 expression of NSCLC-type lung cancer compared with healthy individuals, and using the RT-PCR for ease and rapidity it can be proved.
Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17(3):13.46-8
Zheng YW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest. 2013;31(3):197-205.
Goldstraw P, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727-40.
Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009;54(1): 12-27.
Derman BA, et al. Treatment of advanced squamous cell carcinoma of the lung: A review. Translational Lung Cancer Research. 2015;(4):524-532.
Pardo J, et al. Large cell carcinoma of the lung: An endangered species? Appl Immunohistochem Mol Morphol. 2009;17(5):383-92.
Deng L, et al. Association of PDCD1 and CTLA-4 gene expression with clinicopathological factors and survival in non-small-cell lung cancer: Results from a large and pooled microarray database. J Thorac Oncol. 2015;10(7):1020-6.
Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-95.
Dong H, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365-9.
Latchman Y, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-8.
Yamazaki T, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169(10):5538-45.
Freeman GJ, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.
Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
Wu C, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):9-24.
Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25-39.
Zhang X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):37-47.
Sidorenko SP, Clark EA. The dual- function CD150 receptor subfamily: The viral attraction. Nat Immunol. 2003;4(1):19-24.
Okazaki T, et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA. 2001;98(24):13866-71.
Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-53.
Sheppard KA, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1-3):37-41.
Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: Inducible co-stimulator and PD-1. Curr Opin Immunol. 2002;14(6):779-82.
Greenwald RJ, GJ Freeman GJ, AH Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48.
Nishimura H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-51.
Iwai Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293-7.
Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-96.
Raimondi G, et al. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006;176(5):2808-16.
Bally APR, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression. Journal of Immunology (Baltimore, Md. : 1950). 2016;196(6):2431-2437.
Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171-2186.